ClinicalTrials.gg
Not yet recruitingNCT07529080Updated Oct 15, 2026

Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial

An interventional study of Internet-Based Intervention and Internet-Based Intervention in Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm and Melanoma, sponsored by University of Michigan Rogel Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 15, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 167 studies in Testicular Neoplasms with a site in United States — 21 open to participants now, 26 under way, 1 of them phase 3. Testicular Neoplasms · United States.

Planned enrollment
19th of 111
142 · median 36
Started
2026
with 5 others
No phase
25 of 167
6 open now
Primary completion
2027-12
later than 10 of 25 live
Registered
167th of 167
by date

Among the 167 studies in Testicular Neoplasms with a site in United States, this one is the 19th largest by planned enrollment of the 111 interventional ones that give a count, is one of 6 that started in 2026, is one of 25 with no phase, reaches primary completion later than 10 of the 25 other live ones, and was the 167th registered.

Testicular Neoplasms

295 studies on the registry are indexed under Testicular Neoplasms; 51 are open to participants now.

Browse Testicular Neoplasms studies →

Open to participants now

21 of the 167 studies in Testicular Neoplasms with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 20 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Testicular Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial support - to a support tool providing cancer-specific information alone (minus psychosocial modules). This tool, called Thrive Track, will be for YA patients aged 20-39 with thyroid, melanoma, or testicular cancer. Young adult survivors frequently experience persistent worry and distress that can interfere with coping and reduce quality of life. They are also particularly vulnerable to the emotional impact of cancer and may not have adequate support to manage these concerns. The enhanced version of Thrive Track includes personalized emotional support content and strategies designed to help patients better manage worry and distress. Adding these emotional support tools may provide greater benefit than survivorship education alone in strengthening young adult survivors' ability to manage their emotional well-being.

03

Conditions studied

  • Differentiated Thyroid Gland Carcinoma
  • Malignant Testicular Neoplasm
  • Melanoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Papillary Carcinoma
04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PARTICIPANTS RECRUITED FROM SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS PROGRAM (SEER)-GEORGIA: Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer), melanoma, or testicular cancer at any stage and reported to the SEER-Georgia registry
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: 2-10 years after diagnosis with cancer
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: English speaking (able to read and speak English)
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Residing in the United States
  • PARTICIPANTS RECRUITED FROM THYROID CANCER SURVIVORS' ASSOCIATION INC. (THYCA): Age 18-37 at time of cancer diagnosis and age 20-39 at time of enrollment
  • PARTICIPANTS RECRUITED FROM THYCA: Diagnosed with differentiated thyroid cancer (papillary or follicular thyroid cancer) at any stage
  • PARTICIPANTS RECRUITED FROM THYCA: 2-10 years after diagnosis with cancer
  • PARTICIPANTS RECRUITED FROM THYCA: English speaking (able to read and speak English)
  • PARTICIPANTS RECRUITED FROM THYCA: Report of any cancer-related worry (on a 5-point Likert scale from not at all to very worried; those who indicate "not at all" will be told the study is focused on those who experience worry)
  • PARTICIPANTS RECRUITED FROM THYCA: Residing in the United States

Exclusion criteria

Exclusion Criteria:

  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects from certain vulnerable populations will be excluded as appropriate: fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)

    • It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman
  • PARTICIPANTS RECRUITED FROM SEER-GEORGIA: Subjects that do not meet the inclusion criteria
  • PARTICIPANTS RECRUITED FROM THYCA: Subjects from certain vulnerable populations will be excluded as appropriate fetuses, neonates, children under age 18, prisoners, institutionalized individuals, or others who may be considered vulnerable populations per the National Institutes of Health (NIH) and Office for Human Research Protections (OHRP)

    • It is possible that a subject might be pregnant. Because this involves surveys and reviewing an informational website, participation should have no additional risk for a pregnant woman
  • PARTICIPANTS RECRUITED FROM THYCA: Subjects that do not meet the inclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
142 participants (estimated)

Study arms

  • Active comparator
    Arm I (Thrive control)

    Patients receive access to Thrive Track website with general cancer-specific survivorship care information for up to 3 months.

    Other: Internet-Based Intervention · Other: Interview · Other: Questionnaire Administration

  • Experimental
    Arm II (Thrive Track with emotional support)

    Patients receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content for up to 3 months.

    Other: Internet-Based Intervention · Other: Interview · Other: Questionnaire Administration

Interventions

  • OtherInternet-Based Intervention

    Receive access to Thrive Track website with general cancer-specific survivorship care information

  • OtherInternet-Based Intervention

    Receive access to Thrive Track website with general cancer-specific survivorship care information in addition to emotional support content

  • OtherInterview

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Cancer related worry

    Cancer-related worry will be evaluated using two 8-item validated scales: 1. Cancer Worry Scale (CWS) 2. An adapted cancer worry scale Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the two scales between intervention and control subjects at 3 months post intervention. Scores on the CWS scale range from 8 (minimum) to 32 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes. Scores on the adapted cancer worry scale range from 8 (minimum) to 40 (maximum), with lower scores indicating less cancer-related worry and more favorable outcomes.

    Time frame: 3 months post-enrollment

  2. Cancer related distress

    Cancer-related distress will be measured using the National Comprehensive Cancer Network Distress Thermometer. Scores on the NCCN Distress Thermometer range from 0 (minimum) to 10 (maximum), with lower scores indicating less distress and more favorable outcomes. Overall as well as stratified analyses (by recruitment source and cancer type) will be performed. We will compare mean scores on the distress thermometer between the intervention and control subjects at 3 months post-intervention using two-sample t-tests.

    Time frame: 3 months post-enrollment

Secondary outcomes

  1. Knowledge about worry self-management

    This outcome will be evaluated using a team-developed 4-item scale. Scores on this scale range from 4 (minimum) to 16 (maximum), with higher scores indicating better knowledge about how to self-manage worry and more favorable outcomes.

    Time frame: 3 months post-enrollment

  2. Confidence/self-efficacy in the ability to self-manage worry

    This outcome will be evaluated using an 11-item scale from the Breast Cancer Self Efficacy Scale (BCSE), adapted for all cancers. Scores on this scale range from 11 (minimum) to 55 (maximum), with higher scores indicating better self efficacy to manage cancer-related worry and more favorable outcomes.

    Time frame: At 3 months post-enrollment

  3. Resilience

    This outcome will be evaluated using a 6-item validated scale, adapted from the Communication and Attitudinal Self-Efficacy Scale (CASE) and the Cancer Control and Outlook Scale. Scores on this scale range from 6 (minimum) to 30 (maximum), with higher scores indicating better resilience to deal with cancer and more favorable outcomes.

    Time frame: At 3 months post-enrollment

  4. Ease of tool use

    This outcome will be evaluated using a series of 7 questions designed to help understand the participants' experience using the Thrive Track website.

    Time frame: At 3 months post-enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — As described in our Data Management and Sharing plan (DMS), all the final data generated from this study will be de-identified and uploaded to the Inter-University Consortium for Political and Social Research (ICPSR). Additionally, the primary outcome results of the study will be reported to ClinicalTrials.gov no later than 1 year after the primary completion date of the trial.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: At the end of the study period

Access criteria: Final data generated from this trial can be requested from ICPSR. All researchers requesting the data will need to complete a questionnaire that will include investigator name(s), institution(s), discipline(s), and initial research question(s). We also shall request each applicant to submit to ICPSR the citations of any peer-reviewed presentations and publications. No data-sharing agreement will be required. This data will be accessible for 10 years after it has been uploaded to the ICPSR.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 31 interventional studies with no phase under Testicular Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 72. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jul 2026 → Dec 2026, primary completion Aug 2027 → Dec 2027 and completion Aug 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Apr 14, 2026
StartEst.
Dec 2026was Jul 2026
Primary completionEst.
Dec 2027was Aug 2027
CompletionEst.
Dec 2027was Aug 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Dec 2026
Oct 15, 2026
Primary completion
Aug 2027→Dec 2027
Oct 15, 2026
Study completion
Aug 2027→Dec 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Jul 2026→Dec 2026
    Primary completion Aug 2027→Dec 2027
    Study completion Aug 2027→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07529080
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Megan Haymart, MD
Contact
support@thrivetrack.study
734-615-6745
Megan R Haymart, MD
principal investigator · University of Michigan Rogel Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion